Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Apple's Return on Invested Capital Overview

Pulled from Benzinga Pro data, Apple (NASDAQ:AAPL) posted Q2 earnings of $25.01 billion, an increase from Q1 of 27.78%. Sales dropped to $97.28 billion, a 21.52% decrease between quarters.

Benzinga

Hertz Global Holdings Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Hertz Global Holdings (NASDAQ:HTZ) earned $426.00 million, a 262.6% increase from the preceding quarter. Hertz Global Holdings's sales decreased to $1.81 billion, a 7.13% change since Q4.

Benzinga

Looking Into Solid Biosciences's Return On Capital Employed

Solid Biosciences (NASDAQ:SLDB) brought in sales totaling $1.93 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 36.1%, resulting in a loss of $25.33 million.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Faro Technologies's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q1, Faro Technologies's (NASDAQ:FARO) reported sales totaled $76.66 million. Despite a 69.45% increase in earnings, the company posted a loss of $9.69 million.

Benzinga

Repligen's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, Repligen (NASDAQ:RGEN) earned $46.96 million, a 61.33% increase from the preceding quarter. Repligen also posted a total of $206.40 million in sales, a 10.66% increase since Q4.

Benzinga

Looking Into Surmodics's Return On Capital Employed

Surmodics (NASDAQ:SRDX) brought in sales totaling $26.11 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 45.2%, resulting in a loss of $4.08 million.

Benzinga

Coherus and Junshi Biosciences Receive CRL from FDA for Toripalimab in combination with Gemcitabine and Cisplatin In metastatic nasopharyngeal carcinoma (NPC)

Shanghai Junshi Biosciences and Coherus BioSciences, Inc. (NASDAQ: CHRS) received a complete response letter (CRL) from the U.S.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings for Viper Energy Partners

Viper Energy Partners (NASDAQ:VNOM) has observed the following analyst ratings within the last quarter:

Benzinga

How Is The Market Feeling About Vaxxinity?

Vaxxinity's (NASDAQ:VAXX) short percent of float has risen 32.76% since its last report. The company recently reported that it has 278.70 thousand shares sold short, which is 0.77% of all regular shares that are available for trading.

Benzinga

Spirit Airlines Rejects JetBlue's Takeover Bid; JetBlue Renews Offer

Spirit Airlines, Inc. (NYSE: SAVE) has rejected the acquisition bid from JetBlue Airways Corp (NASDAQ: JBLU) and will proceed with the previously-announced merger agreement with Frontier Group Holdings, Inc.

Benzinga

4 Analysts Have This to Say About Cowen

Within the last quarter, Cowen (NASDAQ:COWN) has observed the following analyst ratings:

Benzinga

Where Nerdwallet Stands With Analysts

Analysts have provided the following ratings for Nerdwallet (NASDAQ:NRDS) within the last quarter:

Benzinga

Analyst Ratings for Honeywell Intl

Honeywell Intl (NASDAQ:HON) has observed the following analyst ratings within the last quarter:

Benzinga

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Akoustis Registers 83% Revenue Growth In Q3; Adds Another Tier-1 5G Mobile RF Module Customer

Akoustis Technologies, Inc (NASDAQ:AKTS) reported third-quarter FY22 revenue growth of 83% year-on-year (25% Q/Q) to $4.61 million, missing the consensus of $4.70 million. Non-GAAP EPS loss of $(0.27) missed the consensus loss of $(0.22). Akoustis held $55.9 million in cash and equivalents. CEO Jeff Shealy stated, "Despite the persistent macro headwinds presented by…

Benzinga

Lordstown, Foxconn Postponed Ohio Factory Sale Deadline

Lordstown Motors Corp (NASDAQ:RIDE) agreed to push back the deadline to sell its Ohio factory to Hon Hai Precision Industry Co Ltd (OTC:HNHPF), operating as Foxconn, Bloomberg reports. The struggling EV startup needs to repay Foxconn if the deal does not close by May 14. Foxconn acknowledged that the two sides were still negotiating…

Benzinga

Why ON Semiconductor Shares Are Rising

ON Semiconductor Corp (NASDAQ: ON) shares are trading higher by 3.93% to $54.16 during Monday’s pre-market session. The company announced better-than-expected first-quarter adjusted EPS and sales results and issued second-quarter adjusted EPS and sales guidance above estimates.

Benzinga

How To Attend ACM Research Q1 2022 Earnings Conference Call

ACM Research (NASDAQ:ACMR) will host a conference call at 08:00 AM ET on May 6, 2022, to discuss Q1 2022 earnings results. How to Attend ACM Research (ACMR) Conference Call Follow this link to access the live webcast.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

As Expected, FDA Rejects Axsome Therapeutics' Migraine Candidate

The FDA has issued a Complete Response Letter (CRL) to Axsome Therapeutics Inc's (NASDAQ:AXSM) AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval…

Benzinga

Why Vertex Pharmaceuticals Shares Are Falling

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday’s pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to support do

Benzinga

Zosano Pharma Announces Additional Workforce Layoff

The FDA had granted Zosano Pharma Corporation (NASDAQ: ZSAN) a twelve-month extension to April 20, 2023, to resubmit its M207 marketing application.

Benzinga

Executives Buy Around $1.6M Of 4 Penny Stocks

US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading…

Benzinga

Itron: Q1 Earnings Insights

Itron (NASDAQ:ITRI) reported its Q1 earnings results on Monday, May 2, 2022 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Itron beat estimated earnings by 37.5%, reporting an EPS of $0.11 versus an estimate of $0.08.

Benzinga

Executives Buy More Than $32M Of 3 Stocks

Although US stocks closed sharply lower on Friday, there were a few notable insider trades.

Benzinga

FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma

The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma.

1 … 662 663 664 665

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

US Food and Drug Administration

63 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.